FDA Orange Book · active-ingredient family
Irinotecan hydrochloride
Irinotecan hydrochloride: 2 brands, 26 generics; first approved Jun 14, 1996; generic available.
Generic available2 exclusivity periodsHas discontinued products
Generic status & protection
Generic available: 26 ANDA applications approved.
Earliest patent expiry Latest exclusivity ends
Brands (NDA)
2
Generics (ANDA)
26
Listed patents
14
Next patent expiry
Jan 06, 2027
in 2 mo
Brand (NDA) products
Originator applications
- IPSENNDA 2077932015
Approved strengths under this FDA application. Strength Dosage form Route Status TE EQ 43MG BASE/10ML (EQ 4.3MG BASE/ML) INJECTABLE, LIPOSOMAL INTRAVENOUS Rx - - PFIZER INCNDA 02057119963 strengths
Approved strengths under this FDA application. Strength Dosage form Route Status TE 40MG/2ML (20MG/ML) INJECTABLE INJECTION Rx AP 100MG/5ML (20MG/ML) INJECTABLE INJECTION Rx AP 300MG/15ML (20MG/ML) INJECTABLE INJECTION Rx AP
Generic (ANDA) products (26)
Abbreviated applications
- IRINOTECAN HYDROCHLORIDEEUGIA PHARMAANDA 21327820204 strengths
Approved strengths under this FDA application. Strength Dosage form Route Status TE 40MG/2ML (20MG/ML) INJECTABLE INJECTION Rx AP 100MG/5ML (20MG/ML) INJECTABLE INJECTION Rx AP 300MG/15ML (20MG/ML) INJECTABLE INJECTION Rx AP 500MG/25ML (20MG/ML) INJECTABLE INJECTION Rx AP - IRINOTECAN HYDROCHLORIDEGLANDANDA 21299320192 strengths
Approved strengths under this FDA application. Strength Dosage form Route Status TE 40MG/2ML (20MG/ML) INJECTABLE INJECTION Rx AP 100MG/5ML (20MG/ML) INJECTABLE INJECTION Rx AP - IRINOTECAN HYDROCHLORIDEADAPTISANDA 20871820183 strengths
Approved strengths under this FDA application. Strength Dosage form Route Status TE 40MG/2ML (20MG/ML) INJECTABLE INJECTION Rx AP 100MG/5ML (20MG/ML) INJECTABLE INJECTION Rx AP 300MG/15ML (20MG/ML) INJECTABLE INJECTION Rx AP - IRINOTECAN HYDROCHLORIDEINTAS PHARMS USAANDA 20305420172 strengths
Approved strengths under this FDA application. Strength Dosage form Route Status TE 40MG/2ML (20MG/ML) INJECTABLE INJECTION Rx AP 100MG/5ML (20MG/ML) INJECTABLE INJECTION Rx AP - IRINOTECAN HYDROCHLORIDEINGENUS PHARMS LLCANDA 20693520172 strengths
Approved strengths under this FDA application. Strength Dosage form Route Status TE 40MG/2ML (20MG/ML) INJECTABLE INJECTION Rx AP 100MG/5ML (20MG/ML) INJECTABLE INJECTION Rx AP - IRINOTECAN HYDROCHLORIDEQILU PHARM HAINANANDA 20338020163 strengths
Approved strengths under this FDA application. Strength Dosage form Route Status TE 40MG/2ML (20MG/ML) INJECTABLE INJECTION Rx AP 100MG/5ML (20MG/ML) INJECTABLE INJECTION Rx AP 300MG/15ML (20MG/ML) INJECTABLE INJECTION Rx AP - IRINOTECAN HYDROCHLORIDEEMCURE PHARMS LTDANDA 20077120122 strengths
Approved strengths under this FDA application. Strength Dosage form Route Status TE 40MG/2ML (20MG/ML) INJECTABLE INJECTION Discontinued - 100MG/5ML (20MG/ML) INJECTABLE INJECTION Discontinued - - IRINOTECAN HYDROCHLORIDEHENGRUI PHARMAANDA 09067520112 strengths
Approved strengths under this FDA application. Strength Dosage form Route Status TE 100MG/5ML (20MG/ML) INJECTABLE INJECTION Discontinued - 40MG/2ML (20MG/ML) INJECTABLE INJECTION Discontinued - - IRINOTECAN HYDROCHLORIDEPHARMOBEDIENTANDA 09039320112 strengths
Approved strengths under this FDA application. Strength Dosage form Route Status TE 40MG/2ML (20MG/ML) INJECTABLE INJECTION Rx AP 100MG/5ML (20MG/ML) INJECTABLE INJECTION Rx AP - IRINOTECAN HYDROCHLORIDEHIKMA FARMACEUTICAANDA 09103220102 strengths
Approved strengths under this FDA application. Strength Dosage form Route Status TE 40MG/2ML (20MG/ML) INJECTABLE INJECTION Rx AP 100MG/5ML (20MG/ML) INJECTABLE INJECTION Rx AP - IRINOTECAN HYDROCHLORIDECHARTWELL RXANDA 07895320102 strengths
Approved strengths under this FDA application. Strength Dosage form Route Status TE 40MG/2ML (20MG/ML) INJECTABLE INJECTION Discontinued - 100MG/5ML (20MG/ML) INJECTABLE INJECTION Discontinued - - IRINOTECAN HYDROCHLORIDESANDOZANDA 09013720092 strengths
Approved strengths under this FDA application. Strength Dosage form Route Status TE 40MG/2ML (20MG/ML) INJECTABLE INJECTION Discontinued - 100MG/5ML (20MG/ML) INJECTABLE INJECTION Discontinued - - IRINOTECAN HYDROCHLORIDEEPIC PHARMA LLCANDA 09072620092 strengths
Approved strengths under this FDA application. Strength Dosage form Route Status TE 40MG/2ML (20MG/ML) INJECTABLE INJECTION Rx AP 100MG/5ML (20MG/ML) INJECTABLE INJECTION Rx AP - IRINOTECAN HYDROCHLORIDEHISUN PHARM HANGZHOUANDA 09001620092 strengths
Approved strengths under this FDA application. Strength Dosage form Route Status TE 40MG/2ML (20MG/ML) INJECTABLE INJECTION Discontinued - 100MG/5ML (20MG/ML) INJECTABLE INJECTION Discontinued - - IRINOTECAN HYDROCHLORIDEHIKMAANDA 07875320082 strengths
Approved strengths under this FDA application. Strength Dosage form Route Status TE 40MG/2ML (20MG/ML) INJECTABLE INJECTION Rx AP 100MG/5ML (20MG/ML) INJECTABLE INJECTION Rx AP - IRINOTECAN HYDROCHLORIDEACCORD HLTHCAREANDA 07906820082 strengths
Approved strengths under this FDA application. Strength Dosage form Route Status TE 40MG/2ML (20MG/ML) INJECTABLE INJECTION Rx AP 100MG/5ML (20MG/ML) INJECTABLE INJECTION Rx AP - IRINOTECAN HYDROCHLORIDEPLIVA LACHEMAANDA 07812220082 strengths
Approved strengths under this FDA application. Strength Dosage form Route Status TE 40MG/2ML (20MG/ML) INJECTABLE INJECTION Discontinued - 100MG/5ML (20MG/ML) INJECTABLE INJECTION Discontinued - - IRINOTECAN HYDROCHLORIDESUN PHARMA GLOBALANDA 07880520082 strengths
Approved strengths under this FDA application. Strength Dosage form Route Status TE 40MG/2ML (20MG/ML) INJECTABLE INJECTION Discontinued - 100MG/5ML (20MG/ML) INJECTABLE INJECTION Discontinued - - IRINOTECAN HYDROCHLORIDEACTAVIS TOTOWAANDA 07858920083 strengths
Approved strengths under this FDA application. Strength Dosage form Route Status TE 40MG/2ML (20MG/ML) INJECTABLE INJECTION Rx AP 100MG/5ML (20MG/ML) INJECTABLE INJECTION Rx AP 500MG/25ML (20MG/ML) INJECTABLE INJECTION Rx AP - IRINOTECAN HYDROCHLORIDEFRESENIUS KABI USAANDA 07777620082 strengths
Approved strengths under this FDA application. Strength Dosage form Route Status TE 40MG/2ML (20MG/ML) INJECTABLE INJECTION Rx AP 100MG/5ML (20MG/ML) INJECTABLE INJECTION Rx AP - IRINOTECAN HYDROCHLORIDEFRESENIUS KABI USAANDA 07818820082 strengths
Approved strengths under this FDA application. Strength Dosage form Route Status TE 40MG/2ML (20MG/ML) INJECTABLE INJECTION Discontinued - 100MG/5ML (20MG/ML) INJECTABLE INJECTION Discontinued - - IRINOTECAN HYDROCHLORIDEHOSPIRAANDA 07791520082 strengths
Approved strengths under this FDA application. Strength Dosage form Route Status TE 40MG/2ML (20MG/ML) INJECTABLE INJECTION Rx AP 100MG/5ML (20MG/ML) INJECTABLE INJECTION Rx AP - IRINOTECAN HYDROCHLORIDERSHOSPIRAANDA 0787962008
Approved strengths under this FDA application. Strength Dosage form Route Status TE 500MG/25ML (20MG/ML) INJECTABLE INJECTION Rx AP - IRINOTECAN HYDROCHLORIDESANDOZANDA 07799420082 strengths
Approved strengths under this FDA application. Strength Dosage form Route Status TE 40MG/2ML (20MG/ML) INJECTABLE INJECTION Discontinued - 100MG/5ML (20MG/ML) INJECTABLE INJECTION Discontinued - - IRINOTECAN HYDROCHLORIDETEVA PHARMS USAANDA 09010120083 strengths
Approved strengths under this FDA application. Strength Dosage form Route Status TE 500MG/25ML (20MG/ML) INJECTABLE INJECTION Rx AP 40MG/2ML (20MG/ML) INJECTABLE INJECTION Discontinued - 100MG/5ML (20MG/ML) INJECTABLE INJECTION Discontinued - - IRINOTECAN HYDROCHLORIDECIPLA LTDANDA 07721920082 strengths
Approved strengths under this FDA application. Strength Dosage form Route Status TE 40MG/2ML (20MG/ML) INJECTABLE INJECTION Discontinued - 100MG/5ML (20MG/ML) INJECTABLE INJECTION Discontinued -
Patent & exclusivity timeline
Protection horizon
Patent expiryExclusivity endToday
Marketing exclusivity
Hatch-Waxman
- I-932New indication exclusivity (3 years)
in 4 mo
- ODE-463Orphan-drug exclusivity (7 years)
in 4 yr 4 mo
Listed patents
Orange Book patent file
| Patent | Expires | In | Type |
|---|---|---|---|
| 8329213 | in 2 mo | SubstanceProduct | |
| 8147867 | in 1 yr 11 mo | SubstanceProduct | |
| 9717724 | in 6 yr 9 mo | U-2091 | |
| 9492442 | in 6 yr 9 mo | U-1917 | |
| 9364473 | in 6 yr 9 mo | U-1856 | |
| 12364691 | in 6 yr 9 mo | U-1848 | |
| 11369597 | in 6 yr 9 mo | U-1848 | |
| 9339497 | in 6 yr 9 mo | U-1848 | |
| 9452162 | in 6 yr 9 mo | U-1899 | |
| 10980795 | in 6 yr 9 mo | U-1848 | |
| 11344552 | in 10 yr | U-3824 | |
| 12059497 | in 10 yr 1 mo | Product | |
| 10456360 | in 10 yr 1 mo | Product | |
| 10993914 | in 10 yr 1 mo | Product |
Approval history
FDA approval span
First approval
30 yr 10 mo ago
Most recent approval
4 yr 7 mo ago
Approvals span 1996–2022 across 28 FDA applications.
Brand (NDA) 27%
Generic (ANDA) 2693%
Irinotecan hydrochloride: frequently asked questions
Generics, reference-listed drug, patents, and exclusivity for this active ingredient, from the FDA Orange Book.
Built directly from the FDA Orange Book data file (products, patents, and exclusivity). TE codes, RLD/RS flags, patent expirations, and exclusivity dates match the official FDA record. Listed patents reflect those the NDA holder submits under 21 U.S.C. 355 and are not exhaustive.
Related FDA reference tools
- FDA Purple BookLicensed biologics, biosimilars, interchangeables, BLA records, and exclusivity dates.
- FDA BiosimilarsFDA-approved biosimilars and interchangeable biosimilars, by reference product.
- 510(k) Predicate DatabaseSearch FDA 510(k) clearances and map predicate-device lineage.
- FDA 483 DatabaseFDA Form 483 observations and inspection records by firm, date, and citation.
Assyro Intelligence
Ask anything about Irinotecan hydrochloride
Cited answers from FDA, EMA, Health Canada, PubMed and ClinicalTrials.gov, in seconds. Free, no sign-up.
Evaluating for a team? Book a demo